Drug intelligence / Profile preview

rituximab biosimilar RGB-03

Development stage: Phase 1
Lead developer: Gedeon Richter
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RGB-03 is a biosimilar of rituximab, developed by Gedeon Richter. Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes, leading to their depletion. This mechanism is used in the treatment of various diseases, including certain cancers and autoimmune disorders such as rheumatoid arthritis. RGB-03 has been evaluated in clinical trials for its efficacy and safety compared to the reference product MabThera (rituximab), particularly in patients with rheumatoid arthritis[1][2][4].

Other names: rituximab biosimilar

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on rituximab biosimilar RGB-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rituximab biosimilar RGB-03.

Explore the full profile